A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Perampanel (Fycompa)

Noncompetitive AMPA Glutamate Receptor Antagonist class · 3 generic manufacturers · 19 ANDAs filed at FDA.

First FDA approval2012-10-22
Generic availableYes · 3 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$113.0M in CY2024 Part D spend91K claims · 13K beneficiaries · 329 plans surveyed

Lowest NADAC
$4.46/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$22.72
Across all dosage forms in distribution.
Highest NADAC
$31.03
Wide spread — brand-strength NDCs still in market.
Plans with PA
1288 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Perampanel used for?

Perampanel is a Noncompetitive AMPA Glutamate Receptor Antagonist medication tracked in Medicare Part D.

Is there a generic for Perampanel?

Yes. 19 ANDAs filed at FDA, 3 generic manufacturers currently shipping.

How much does my plan pay for Perampanel?

Across 329 Part D plans, Perampanel averages $22.72/unit (NADAC). Lowest available: $4.46/unit. Highest in distribution: $31.03/unit.

Is Perampanel on the FDA shortage list?

No. Perampanel is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.